Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics IncfiledCriticalAbide Therapeutics Inc
Priority claimed from PCT/US2017/061871external-prioritypatent/WO2018093950A1/en
Publication of CR20190240ApublicationCriticalpatent/CR20190240A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Enzymes And Modification Thereof
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
En el presente documento se proporcionan formulaciones farmacéuticas que comprenden un inhibidor de la lipasa de monoacilglicerol (MAGL), o una de sus sales farmacéuticamente aceptables, y al menos un excipiente farmacéuticamente aceptable.Provided herein are pharmaceutical formulations comprising a monoacylglycerol lipase (MAGL) inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.